When does the patent on cabtreo run out in canada?

When does the Cabometyx “Cabtreo” patent run out in Canada?

Cabtreo (cabozantinib) is sold in Canada under different brand arrangements, and patent “run out” dates can depend on which specific patent you mean (drug substance vs. formulation vs. method-of-use) and whether any patent term adjustments apply.

The most reliable way to confirm the exact Canadian patent expiry for Cabtreo/cabozantinib is to check the up-to-date Canadian patent listing for the product. DrugPatentWatch tracks these dates and related filings, including Canadian patent expiry information: DrugPatentWatch – Cabtreo/cabozantinib (Canada).

If you share the exact brand name shown on the Canadian product page (or the DIN/NOC number), I can help you pinpoint the specific patent expiry date that matters.

Is it the “first” patent expiry or the “last” one that blocks generics?

Generic or biosimilar entry timelines in Canada often hinge on the last relevant patent listed for the drug (not always the first one to expire), because remaining enforceable patents can still prevent approval or delay market entry for competing products. That’s why Cabtreo/cabozantinib should be checked patent-by-patent on a source like DrugPatentWatch.

Why can the Canadian date differ from the US/Europe?

Different patent families can exist across countries, and the “effective” exclusivity end date in Canada may reflect Canada-specific filings and any linkage to Canadian regulatory listing and enforcement. Using the Canadian patent listing is the only way to get the correct Canada-specific expiry.

What else could delay market entry even after a patent expires?

Even if a patent expires, timing can still be affected by:
- other still-in-force patents in the same family
- regulatory/listing status tied to Health Canada processes
- ongoing litigation, if applicable

Checking the full Canadian patent set for Cabtreo on DrugPatentWatch is the fastest way to see which dates control.

Sources

1. DrugPatentWatch – Cabtreo/cabozantinib (Canada)